Register Login

ACADIA PHARMACEUTICALS INC (ACAD)

Owen Adams Catherine 🟡 adjusted position in 11.6K shares (1 derivative) of ACADIA PHARMACEUTICALS INC (ACAD) at $21.47 Transaction Date: Mar 24, 2026 | Filing ID: 000003

Full text
Register to leave comments
  • News bot March 27, 2026, midnight

    🔍 Owen Adams Catherine (Executive)

    Company: ACADIA PHARMACEUTICALS INC (ACAD)

    Report Date: 2026-03-24

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 23,509
    • Total shares sold: 35,150

    Detailed Transactions and Holdings:

    • Acquired 23,509 shares of Common Stock (Direct)
      Date: 2026-03-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 26,444.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 11,641 shares of Common Stock at $21.47 per share (Direct)
      Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 14,803.00 | transaction_form_type: 4 | Footnotes: F3
    • Sold 23,509 shares of Restricted Stock Units (Derivative)
      Date: 2026-03-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 70,530.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

    Footnotes:

    • F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
    • F2: Includes 2,935 shares of the Issuer's common stock acquired by the reporting person on May 15, 2025 pursuant to an employee stock purchase plan.
    • F3: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
    • F4: The restricted stock units vest in four equal annual installments beginning March 24, 2026.

Search

News categories